Longitudinal assessment of mutation abundance in cfDNA upon treatment. (A) NKTCL-related mutations disappeared during cfDNA monitoring among patients who achieved CR at the end of treatment. (B) NKTCL-related mutations persisted during cfDNA monitoring among patients who did not achieve CR at the end of treatment.